Hims & Hers
D2C telehealth platform spanning weight loss, primary care, sexual health, hair, skin, and mental health. Weight loss includes oral kits, GLP-1 support, app-based care, and prescription management.
Access model
Primarily D2C cash-pay
Editorial note
Compounding posture changed quickly in Mar 2026 after Hims announced a strategic shift toward FDA-approved semaglutide access.
Coverage and cost
Generally cash-pay; insurance not required
Public starting price from $69/mo for oral weight-loss kits; FDA-approved GLP-1 cash-pay pricing varies
Limited / exception-based as of Mar 2026; previously marketed compounded semaglutide more broadly
Market signals
Evidence and positioning
No company-specific peer-reviewed obesity outcomes found in this sweep; marketing leans on medication-label trial data rather than proprietary published results.
This is the lower dB's current read on Hims & Hers's pricing posture, insurance story, medication posture, and evidence signaling.
Source References
6 public references used in this profile. Links open in a new tab for quick verification.
Pricing, insurance coverage, medication availability, and eligibility can change quickly. Verify current details directly with the provider before starting or switching care.